ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,917.11
0.00%
US Tech 100
20,107.20
-0.10%
Dow Jones
43,408.47
0.32%
Brent Oil
73.89
1.44%
Bitcoin
97,854.96
3.69%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Artiva Biotherapeutics Inc (ARTV) Quote

Artiva Biotherapeutics Inc

Artiva Biotherapeutics Inc (ARTV)

NASDAQ
10.96
-0.34
(-3.01%)
Closed November 20 4:00PM
Delayed by 15 minutes
10.96
0.00
( 0.00% )
Pre Market: 7:00AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
10.96
Bid
9.90
Ask
12.10
Volume
-
0.00 Day's Range 0.00
9.68 52 Week Range 17.31
Market Cap
266.211M
Previous Close
10.96
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
141,878
Shares Outstanding
24,289,328
Dividend Yield
-
PE Ratio
-9.27
Earnings Per Share (EPS)
-1.18
Revenue
33.49M
Net Profit
-28.72M

About Artiva Biotherapeutics Inc

Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (... Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patients treatment location, making them what we believe to be off-the-shelf. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.artivabio.com
Headquarters
Dover, Delaware, USA
Founded
-
Artiva Biotherapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ARTV. The last closing price for Artiva Biotherapeutics was $10.96. Over the last year, Artiva Biotherapeutics shares have traded in a share price range of $ 9.68 to $ 17.31.

Artiva Biotherapeutics currently has 24,289,328 shares outstanding. The market capitalization of Artiva Biotherapeutics is $266.21 million. Artiva Biotherapeutics has a price to earnings ratio (PE ratio) of -9.27.

Ask ADVFN Intelligence (AI)

ARTV Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 12 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 12 2024
Edgar (US Regulatory)

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune...

November 12 2024
GlobeNewswire Inc.

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...

November 11 2024
GlobeNewswire Inc.

Form 8-K - Current report

October 22 2024
Edgar (US Regulatory)

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...

October 22 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

September 13 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

September 13 2024
Edgar (US Regulatory)

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...

September 10 2024
GlobeNewswire Inc.

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK®...

August 29 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.21-9.9424815119112.1712.17105620010.556803CS
4-0.06-0.544464609811.0215.499.685548411.63717425CS
12-0.14-1.2612612612611.117.319.6814187812.49466774CS
26-5.04-31.51617.319.6813876312.17214305CS
52-5.04-31.51617.319.6813876312.17214305CS
156-5.04-31.51617.319.6813876312.17214305CS
260-5.04-31.51617.319.6813876312.17214305CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
$ 1.98
(102.04%)
16.34M
AKTSAkoustis Technologies Inc
$ 0.1321
(51.66%)
57.77M
PETWag Group Company
$ 0.303
(44.22%)
18.31M
ESGROEnstar Group Ltd
$ 28.00
(40.92%)
28
CCECCapital Clean Energy Carriers Corporation
$ 24.99
(34.72%)
11
WSBFWaterstone Financial Inc
$ 9.00
(-40.98%)
4
TRSTriMas Corporation
$ 15.62
(-40.79%)
3
BCAXBicara Therapeutics Inc
$ 11.00
(-40.15%)
212
PYXSPyxis Oncology Inc
$ 2.43
(-36.39%)
209.56k
XNCRXencor Inc
$ 15.11
(-36.30%)
2
AKTSAkoustis Technologies Inc
$ 0.1321
(51.66%)
57.77M
PETWag Group Company
$ 0.303
(44.22%)
18.31M
WORXSCWorx Corporation
$ 1.98
(102.04%)
16.34M
XTKGX3 Holdings Company Ltd
$ 0.0775
(-13.89%)
10.83M
CRKNCrown Electrokinetics Corporation
$ 0.9853
(25.41%)
5.59M

Discussion

View Full Feed
WooptdooU WooptdooU 33 seconds ago
Did OLED stop without GRIFTER lebby? No, it thrived...CORPORATE WELFARIST, GRIFTER lebby needs to go. Let's see if the pic industry likes a guy likes him after all...
LWLG
WebSlinger WebSlinger 1 minute ago
>

That is a completely false narrative.

The last time, SMCI didn't report financials for about a year (between Nov 2017 and Aug 2018) and they had received 7 Notices of Delisting before they
SMCI
misterfishman misterfishman 2 minutes ago
I say forget about this one and come back in a year go trade other plays while this one grows ,if one keep watching this everyday then the impatience and frustration will only drive one nuts.
IGPK
blanka blanka 3 minutes ago
lol you been saying that since $30k
BTCUSD
JOoa0ky JOoa0ky 3 minutes ago
They'd have to sell all their shares prior to accepting the position.
Hence why John Paulson -declined-
FNMA
eagpup eagpup 4 minutes ago
I hope nexboard does have great success? However, I have heard these great stories of the next best things that will disrupt and be successful. I am at the prove it to me stage. I would like to be part of a penny stock that beats the odds. But the reality is, few penny stocks make it. Put up or I am
XERI
Iggy_Bot Iggy_Bot 4 minutes ago
Just a “Elderly Man with a Poor Memory”
PonkenPlonken PonkenPlonken 5 minutes ago
Does anyone in here believe SAVA is a scam? Ph3 results coming soon and they already went above and beyond to cheat on the ph1 and ph2 data set. The ph3 data set will be impossible to skew I believe.
GBR GBR 6 minutes ago
In yesterdays Needham conference,

RS said they had 485 employees
VERI
misterfishman misterfishman 6 minutes ago
Of course. Rome conquered and robbed everybody at the time.
IGPK
Truth_is_a_tool Truth_is_a_tool 6 minutes ago
Or not lol . Oh well. Maybe next week 🤷‍♂️
KBLB
Thomas@yahoo Thomas@yahoo 7 minutes ago
Welcome Back and Now Our 47th PRESIDENT OF THE UNITED STATES DONALD J. TRUMP
https://www.marijuanamoment.net/dr-oz-could-elevate-medical-marijuana-support-as-trumps-medicare-and-medicaid-director/

https://www.marijuanamoment.net/fda-approves-long-awaited-clinical-trial-of-smoke
CVSI
IB_ IB_ 7 minutes ago
As we both know "nasrat said" is not even close to a guarantee !!!!!!!!!!!

I only go by what "nasrat did" .....

How many ANDA's has "nasrat said" would be filed in 2024 ???????????

How many were actually filed ???????????

Hey Thanks A Lot
ELTP
GBR GBR 7 minutes ago
Well my take on that is much of the underlying tech with aiWARE is from AWS.

I think aiWARE is basically a patented framework. Using open source tech and AWS tech, but applying it to their own proprietary patented framework or AI operating system as they call it.

Eve
VERI
Konaploinks Konaploinks 7 minutes ago
Up early. Fell asleep early. Watching Fox News. Charles Payne just mentioned he is watching quantum computing to what’s his name? Anyway what his name says oh. Quantum computing? Then it switches to end of segment on to Carly shimkus ? And she says. Quantum computing? I’m going to have to google tha
IONQ
mrMadMax mrMadMax 7 minutes ago
🤡We will give a free tricycle to these two clowns🤡, Jimr1717 and Pickme2, so you can go around and scare "people" with your nonsense. However, nobody will believe this absurdity BS —no one at all. Poor fools; your insinuations are just as ridiculous as you are.🤡 Instead of bo
ATMH
KVM KVM 8 minutes ago
Somebody should just scoop them up for $5 per share and end everyone's misery.
VERI
cashclan cashclan 8 minutes ago
Same reason



You cut and past nothing but left wing opinion articles ...I am just trying to keep up with the Jones.

There is absolutely zero difference other than my posting shed a little more truth.
SHEEPWOLF SHEEPWOLF 8 minutes ago
$ILLR GREEN 12 OF LAST 18 SESSIONS
•STRONG UPTREND INTACT
•ALL DIPS GET EATEN
https://investorshub.advfn.com/uimage/uploads/2024/11/21/buiqeimageedit_36_6627094413.jpg
ILLR
SHEEPWOLF SHEEPWOLF 9 minutes ago
$ILLR GREEN 12 OF LAST 18 SESSIONS
•STRONG UPTREND INTACT
•ALL DIPS GET EATEN
https://investorshub.advfn.com/uimage/uploads/2024/11/21/buiqeimageedit_36_6627094413.jpg
ILLR
quickensupportnumber12 quickensupportnumber12 9 minutes ago
Quicken users, are you stuck with software or account issues? Don’t worry—call +1-888-848-2409 for immediate support. Whether you’re dealing with login troubles, password recovery, or troubleshooting errors, their expert team is available to assist you. Support hours are 5 am to 5 pm PST, seven days
toohot toohot 10 minutes ago
Outstanding post, edbi46! Very well stated for our beloved BIEL. I’ve always preached that patience is the key. And I truly believe that patience is still needed for our beloved BIEL. Just a little longer.




BUY $BIEL$
BIEL
KVM KVM 10 minutes ago
Exactly how do they have the manpower yet they have over 500 employees with a revenue per employee of over 200k. They need at least 225 mil of revs to break even. Their push backed 2026 breakeven projection isn't correct even based on their 30% growth. But again they have never got any #s right.
VERI
Polymer Paul Polymer Paul 12 minutes ago
I think it's pretty obvious... Timelines should have been met... But lebby botched the negotiations being too demanding. And in the end other companies opted for other solutions which probably workout cheaper when you take lebby and marcelli out of the pay packet. This scenario is very very believab
LWLG

Your Recent History

NASDAQ
ARTV
Artiva Biotherapeutics
NASDAQ
ARVN
Arvinas
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved